Today: 8 June 2026
Northern Star share price skids 8% as gold rout rattles ASX miners — what to watch next

Northern Star share price skids 8% as gold rout rattles ASX miners — what to watch next

Sydney, February 2, 2026, 16:46 AEDT — After-hours

  • Northern Star shares fell sharply, dropping 8.1% to close at A$26.60, marking one of the steepest declines among large caps on Monday.
  • The decline followed a steep sell-off in bullion as traders prepared for an increase in futures margin requirements.
  • Attention shifts to Northern Star’s half-year results set for Feb. 12, following guidance cuts in January.

Northern Star Resources shares dropped 8.1% to A$26.60 on Monday, with roughly A$308 million changing hands. That made it one of the most actively traded stocks by value on the market. Newmont Corporation and Evolution Mining also tumbled, highlighting the pressure on gold-linked shares.

Gold prices took a sharp hit following last week’s record surge. Spot gold dropped 3.3% to $4,703.27 an ounce, after tumbling more than 5% earlier in the session. Traders are digesting the CME Group’s decision to raise margin requirements—the cash needed to hold futures positions—as well as the Fed outlook under Donald Trump’s pick, Kevin Warsh. Tim Waterer from KCM Trade pointed to “forced liquidations and margin increases” triggering “a cascading effect.” Reuters

For miners, these shifts are crucial since their profits hinge on the margin between gold prices and production costs. When bullion prices turn volatile, stocks often swing too far, both up and down.

Northern Star is facing timing challenges of its own. In a Jan. 2 operational update, it lowered its FY26 production forecast to 1.6–1.7 million ounces from the previous 1.7–1.85 million, blaming a weak December quarter marked by outages and maintenance problems across its operations. The company highlighted a primary crusher failure at Kalgoorlie Super Pit and warned throughput might remain inconsistent as it shifts to a new, expanded mill. Recovery efforts at Jundee are expected to extend into the March quarter, and grade issues at Pogo also weighed on the outlook.

Costs followed. On Jan. 20, the company bumped its FY26 all-in sustaining cost (AISC) forecast—a key metric covering operating costs, royalties, and ongoing capital—to A$2,600–A$2,800 per ounce, up from A$2,300–A$2,700. Northern Star pointed to softer gold sales and higher royalties, driven by elevated gold prices, as the reasons behind the hike. Sustaining capital guidance remained steady at about A$750 million.

Against this backdrop, investors are left sorting out two trades that often blur together on a red day: unwinding commodities positions and companies grappling with operational issues. Monday leaned heavily toward the former, though it doesn’t rule out the latter.

The risk is that selling in bullion could get messy. Rising margins might push leveraged traders to slash positions quickly, while a stronger U.S. dollar usually weighs on gold. If this dynamic continues, miners could remain under pressure, even without any shifts at the mine gate.

Northern Star’s next major update comes with the half-year results on Feb. 12. Investors will be watching closely for fresh details on production, costs, and capital expenditure following the January guidance revisions. How management positions the upcoming period will also be under scrutiny.

Stock Market Today

  • Stellantis Stock Forecast Amid FaSTLAne 2030 Plan and Tariff Concerns
    June 8, 2026, 9:11 AM EDT. Stellantis (STLAM) trades at €6.13 on 8 June 2026, below late May levels. The automaker's FaSTLAne 2030 plan targets revenue growth to €190bn by 2030, with a 7% adjusted operating margin, backed by a €60bn five-year investment strategy. However, analysts voice mixed views on the stock. Bank of America downgraded Stellantis to Underperform with a €5.50 price target citing competitive pressure from Chinese EV makers. Jefferies maintains a Buy rating, targeting €9.50. MarketScreener's consensus is Hold with a €7.86 average price target. Morgan Stanley raised its target to €7.10, keeping an Equal Weight rating. Public.com reports a Buy consensus for NYSE-listed STLA with an average $11.59 price target. The stock faces risks from rising US tariffs, forecast at €1.60bn for 2026. Past performance is not indicative of future results.

Latest articles

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

8 June 2026
Plug Power rose 2.95% to $3.31 in Monday pre-market trading after a $39.2 million federal tax credit sale tied to its St. Gabriel hydrogen facility, as investors await CEO Jose Luis Crespo’s June 11 update on liquidity and asset sales amid ongoing losses and a recent 10.69% stock drop.
ABAT Shares Jump on DOE’s $115M Lithium Grant Return

ABAT Shares Jump on DOE’s $115M Lithium Grant Return

8 June 2026
American Battery Technology Co shares soared 29.58% to $4.03 premarket after the U.S. Department of Energy fully reinstated a $115 million grant for its Nevada lithium refinery, restoring federal funding for the Tonopah Flats Lithium Project with no change to awarded funds or milestones, though risks remain from permitting, financing, and volatile lithium prices.
NANO Nuclear Stock Bounces, Investors Eye What’s Next

NANO Nuclear Stock Bounces, Investors Eye What’s Next

8 June 2026
NANO Nuclear Energy jumped 7.8% to $25.40 in premarket trading after a 9.9% Friday drop, as traders weighed fresh insider sales filings and recent regulatory progress on its KRONOS microreactor project; the company held $568.7 million in cash as of March 31, but faces sector-wide volatility and execution risks.
Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

8 June 2026
Nurix soared 20.4% to $17.62 premarket after Roche agreed to pay $700 million up front in a bexobrutideg collaboration worth up to $2.3 billion, a major cash boost and external validation for Nurix’s lead blood cancer drug ahead of a planned Phase 3 trial, with Roche’s clinical and commercial backing now in play.
Winbond stock tumbles 8% at the open as Taiwan’s memory trade turns choppy again
Previous Story

Winbond stock tumbles 8% at the open as Taiwan’s memory trade turns choppy again

Telstra share price bucks ASX slide as miners sink; RBA call and Feb results loom
Next Story

Telstra share price bucks ASX slide as miners sink; RBA call and Feb results loom

Go toTop